Structure Therapeutics Inc. is emerging in oral GLP-1 obesity drugs after Phase II success and rivals’ setbacks. Click here ...

Structure Therapeutics develops oral drugs for chronic diseases, with lead assets targeting diabetes, obesity, and cardiovascular care.

In today's rapidly evolving business landscape, the quest for sustainable growth is more critical than ever. As someone who has firsthand experience scaling a company sustainably, I have witnessed the ...